Skip to main content

Table 1 Comparison of patientsā€™ characteristics

From: Clinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: a multicenter retrospective study from Japan

Ā 

With subsequent chemotherapy

nā€‰=ā€‰17

Ā 

Age (year-old)

71 (45ā€“76)

Ā 

Sex (male: female)

13:4

Ā 

Tumor stage IV, n (%)

11 (64.7)

Ā 

ECOG PS (0:1)

17:0

Ā 

Smoking history, n (%)

9 (52.9)

Ā 

Brinkman index

500.0 (0-1530)

Ā 

History of lung disease, n (%)

0 (0)

Ā 

Emphysema on CT scan, n (%)

4 (23.5)

Ā 

Treatment, 1st line vs. later

15 (88.2)

Ā 

CEA (ng/mL)

5.9 (1.3-109.1)

Ā 

CA19-9 (U/mL)

200.4 (2.1ā€“8543.0)

Ā 

KL-6 (U/mL)

356.0 (187.0-1784.0)

Ā 

SP-D (ng/mL)

198.6 (50.2-530.2)

Ā 

ILD grade 1/2/3/4, n (%)

7 (41.1)/6 (35.3)/4 (23.5)/0 (0)

Ā 
  1. ECOG PS Eastern Cooperative Oncology Group Performance Status, CEA carcinoembryonic antigen, CA19-9 cancer antigen 19ā€‰āˆ’ā€‰9, KL-6 Krebs von den Lungen-6 antigen, SP-D surfactant protein D